Latest News
News Functions
Additional Functions
1 June 2023
Apogenix AG
Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
27 March 2023
Apogenix AG
Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme
14 December 2022
Apogenix AG
Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
19 October 2022
Apogenix AG
Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients
9 December 2021
Apogenix AG
Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19
22 December 2020
Apogenix AG
Apogenix AG: COVID-19 targeted treatment trial launched in Vienna
13 October 2020
Apogenix AG
Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial
28 July 2020
Apogenix AG
Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients
17 June 2020
Apogenix AG
Apogenix to Present at AACR Virtual Annual Meeting II
5 December 2019
Apogenix AG
Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress
7 November 2019
Apogenix AG
Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology
10 October 2019
Apogenix AG
Apogenix to Present at Several Upcoming International Conferences
24 September 2019
Apogenix AG
ESMO and Apogenix Collaborate on ‘Recurrent Glioblastoma Management: Challenges and Opportunities’ Colloquium
19 September 2019
Apogenix AG
Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology
2 September 2019
Apogenix AG
Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS
23 July 2019
Apogenix AG
Excellent Preclinical Efficacy Data of Apogenix’ HERA-GITRL Published in Journal for ImmunoTherapy of Cancer
7 May 2019
Apogenix AG
Apogenix to Present at Four Upcoming International Conferences
7 March 2019
Apogenix AG
Apogenix Announces Oral and Poster Presentations at Upcoming International Conferences
18 October 2018
Apogenix AG
Apogenix to Present at Five Upcoming International Conferences
11 October 2018
Apogenix AG
Preclinical Efficacy Data of Apogenix’ HERA-CD40L Published in Journal of Immunotherapy
2 October 2018
Apogenix AG
Preclinical Efficacy Data of Apogenix’ HERA-CD27L Published in Frontiers in Oncology
1 August 2018
Apogenix AG
Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept
23 May 2018
Apogenix AG
Apogenix Provides Update on Clinical Development of Asunercept
5 October 2017
Apogenix AG
Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes
29 May 2017
Apogenix AG
Apogenix Granted PRIME designation by European Medicines Agency for Asunercept to Treat Glioblastoma
26 April 2017
Apogenix AG
Apogenix to Present at Three Upcoming International Conferences
11 April 2017
Apogenix AG
Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
20 March 2017
Apogenix AG
Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)
5 December 2016
Apogenix AG
Apogenix Reports Final Phase I MDS Data at this Year’s American Society of Hematology (ASH) Meeting
4 November 2016
Apogenix AG
Apogenix Reports Significant Progress in Collaboration with CANbridge